Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Verseon Challenges AI Drug Discovery; Can Novel Molecules Pass Validation?

Verseon has challenged one of pharma’s strongest AI drug discovery promises: that data-driven models can consistently create truly novel medicines. In a July 22, 2026 report, the Bay Area drug developer argued that most AI platforms remain tied to known
  • News
Verseon Challenges AI Drug Discovery; Can Novel Molecules Pass Validation?

BMS Builds a Pharma AI Supercomputer: Why Validation Just Got Harder

Bristol Myers Squibb announced on July 20, 2026, that it will expand its artificial intelligence infrastructure through a new NVIDIA DGX SuperPOD equipped with Vera Rubin NVL72 systems. BMS plans to use the infrastructure across several research areas, including oncology,
  • News
BMS Builds a Pharma AI Supercomputer: Why Validation Just Got Harder

MindRank Secures $52M; AI-Designed Drugs Move Beyond Discovery

Artificial intelligence has taken another step from research into regulated drug development. Chinese biotech MindRank has secured $52 million in Series B funding to advance its AI-powered drug discovery platform and accelerate the clinical development of its oral GLP-1 receptor
  • News
MindRank Secures $52M; AI-Designed Drugs Move Beyond Discovery

FDA Quietly Rewrites Drug Repurposing Rules; Pharma Data Validation Suddenly Becomes Critical

The FDA is urging pharmaceutical companies to re-examine decades of clinical and real-world data using AI and advanced analytics to identify new uses for existing drugs. Published on May 29, 2026, this initiative highlights how legacy datasets may still hold
  • News
FDA Quietly Rewrites Drug Repurposing Rules; Pharma Data Validation Suddenly Becomes Critical